Erythropoietin in The UK : A Setback for Gene Patents ?  

Oleh:

Crespi, R. Stephen

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 3 (Mar. 2005), page 367-368.
Topik: gene; erythropoietin; gene patents

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

A decision to invalidate the patent for amgen's blockbuster is ominous for future gene patents. The recently concluded litigation of Kirin-Amgen's erythropoietin patent in the united kingdom courts has added a further chapter to the intriguing saga of recombinant DNA patents and their enforcement. The patent (UK 0148605) derives from an application originally field in the european patent office and covers the use of recombinant DNA technology to produce erythropoietin (EPO), a hormone required for the production of red blood cells. Patents covering it internationally have been the subject of previous litigation in the courts of the US, the Netherlands, Germany, Canada and Australia.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali